Loncastuximab Tesirine
Not recommended HaematologyAuthority RequiredLater-line line
Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received two or more prior lines of systemic therapy.
1
Submissions
2026–26
On the record
Redacted
ICER range
commercial-in-confidence
Redacted
Cost basis
Decision on record
- Meeting Mar 2026 Not recommended Diffuse large B-cell lymphoma (DLBCL)
Cost-effectiveness
ICER values are redacted in the public summary document ('redacted content' appears throughout pricing and economic model sections).
Decision context
PopulationAdults with relapsed or refractory DLBCL who have received 2 or more prior lines of systemic therapy, have previously received or are unsuitable for CAR-T cell therapy, are ineligible for stem cell transplantation, and have previously received or are unable to receive bispecific T-cell engager therapy, with WHO performance status no higher than 2.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2026 | Not recommended | rituximab in combination with ifosfamide, carboplatin, and etoposide (R-ICE) | — | RCT · ORR |